Astellas Pharma Inc. has had a busy and turbulent period. Financial results definitions have changed, and Compass Pathways which has ties with the company plans to cut down 30% of its employees. Astellas just released its half-yearly earnings reports and the market showed increased short interests. However, some AMD and gastric cancer therapies have encountered regulatory obstacles in Europe and the U.S. The company has also been implicated in an indictment case in China. Astellas is making significant strides in advanced Gastric/GEJ cancer treatments, with
VYLOY™ having been approved by the U.S. FDA. They have, anyway, suffered potential currency losses for fiscal year 2024. Astellas has several initiatives in Tanzania, and announced collaboration with
YASKAWA to integrate pharmaceutical and robotics technologies. The company also suffers the closure of its biomanufacturing facility affecting around 100 employees. Their oncology portfolio was spotlighted at the 2024 ASCO annual meeting. Their new centres, a digital health product, and substantial collaborations underscore the firm's constant drive for innovation. Notwithstanding, there are also concerns over a withdrawn $340M licensing deal and the unprofitability of investors from the previous year. However, the company recently got approval for its heart failure digital solution,
DIGITIVA™.
Astellas Pharma Inc. News Analytics from Wed, 28 Oct 2020 07:00:00 GMT to Fri, 01 Nov 2024 22:17:12 GMT -
Rating -1
- Innovation 5
- Information 5
- Rumor -2
